NewAmsterdam Pharma reported GAAP revenue of $19.1 million for the second quarter of 2025, marking a substantial 740% increase from $2.3 million in the prior-year period. This growth was primarily driven by the recognition of a $16.1 million second installment of development cost contributions from the Menarini License.
The company significantly improved its net loss, which narrowed to $17.4 million for Q2 2025 compared to $39.0 million in Q2 2024. This improvement was mainly due to a 28% decrease in research and development expenses to $27.5 million, partially offset by a 65% increase in selling, general and administrative expenses to $27.3 million as commercial preparations advanced.
NewAmsterdam Pharma maintained a robust liquidity position with $783.3 million in cash, cash equivalents, and marketable securities as of June 30, 2025. The European marketing authorization application (MAA) remains on track for the second half of 2025, and the Phase 3 PREVAIL cardiovascular outcomes trial continues as planned.
The company also announced plans to launch the Phase 3 RUBENS trial later this year, which will evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes and metabolic syndrome requiring additional LDL-C lowering. This expansion of the clinical program, alongside the recently announced positive Alzheimer's disease biomarker data, underscores obicetrapib's broad therapeutic potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.